###### Strengths and limitations of this study

-   Use of objective and self-reported outcome measures that represent body functions and activity domains of the International Classification of Functioning, Disability and Health (ICF).

-   Sample size.

-   High baseline scores for primary outcome.

-   Loss to follow-up.

Introduction {#s1}
============

In the past decade, several studies that evaluate the effect of early supported discharge on short-term and long-term outcome after stroke have been published.[@R1] The greatest benefits that such studies show are associated with support from a coordinated multidisciplinary team.[@R4] Early supported discharge combined with adequate resources has been found to reduce long-term physical dependency and the need for admittance to an institution.[@R1] However, rehabilitation models may differ, and the effectiveness of various models should be investigated.

To the best of our knowledge, the effects of early supported discharge on patients' physical capacity, defined as what a person can do in a standard environment,[@R5] have only been examined in three studies. These show no differences in balance and walking between the groups.[@R6] Two of these studies had low statistical power[@R6] [@R7] and all had small sample sizes.[@R6] Thus, changes in physical capacity and comparisons between treatment arms do not seem to have been fully explored. It is therefore desirable to examine change in physical capacity in a larger scale study that compares the effects of various rehabilitation models.

The social and physical context for rehabilitation is considered important to patient outcome.[@R9] Rehabilitation provided at home allows the patient to practise in a real-life environment, which could directly enhance functioning and participation in daily life tasks. Meeting the actual needs of the patients and their families within their own homes could motivate patients more than when training takes place in an outpatient context. At the same time, rehabilitation in a centre could give more focused training on balance and walking, and enhanced training effects.[@R9]

The aim of this study was therefore to compare the effects on balance and walking of three models of stroke rehabilitation: early supported discharge with rehabilitation in a day unit or at home, and traditional uncoordinated treatment (control).

Methods {#s2}
=======

Design overview {#s2a}
---------------

The study was conducted in the context of a larger single-blinded randomised controlled trial (RCT), the Early Supported Discharge after Stroke in Bergen (ESD Stroke Bergen), registered in ClinicalTrials.gov (NCT00771771). The ESD Stroke Bergen had a predetermined inclusion period of 3 years, and the protocol is published.[@R10]

Participants and allocation {#s2b}
---------------------------

The study was conducted at a university hospital in collaboration with the primary healthcare services. The patients were recruited from the hospital stroke unit during the period 8 December 2008 to 20 December 2011. Follow-up assessment was performed 3 months after inclusion and was completed on 29 March 2012. A stroke unit physician assessed eligibility for inclusion. Inclusion criteria: patients had to live in Bergen and at home prior to the stroke, be included within 7 days after stroke onset and between 6 and 120 h after admission to the stroke unit, be awake and have a National Institutes of Health Stroke Scale (NIHSS)[@R11] score of 2--26. Exclusion criteria were serious psychiatric disorder, current alcohol or substance abuse, serious comorbidity such as terminal cancer or insufficient Norwegian language skills. The patients were given a folder containing written information about the study, and their written informed consent was necessary. If this was not possible, consent was given by the next of kin, with written patient confirmation as soon as this became possible. This procedure was approved by the regional ethics committee. For this study, only patients who were discharged directly to their homes from the stroke unit and assessed by the primary outcome measure Postural Assessment Scale for Stroke (PASS)[@R14] were included.

Baseline testing was performed after inclusion and before randomisation for the main study. For allocation of the patients, we used a computer-generated list of random numbers in blocks of six (two patients allocated to each group) generated by an independent researcher at the local university. The person recruiting participants did not have access to the randomisation list. A nurse at the stroke unit was responsible for giving the allocated patients written information about their assigned groups.

Four experienced neurorehabilitation physiotherapists conducted the physical capacity tests of gait and balance and collected related self-reports. To assure standardisation, the physiotherapists underwent a period of training prior to the study in order to learn to use the physical tests. Neurologists were responsible for assessing NIHSS, and trained stroke nurses assessed the Barthel index (BI)[@R15] [@R16] and modified Rankin Scale (mRS)[@R17] at baseline. At 3 months, BI and mRS were administered by a trained physiotherapist. All outcome assessors were blinded to the group of the patient. The patients were retested at the hospital outpatient clinic 3 months after inclusion.

Interventions {#s2c}
-------------

For the experimental groups, two designated coordinated multidisciplinary teams, one hospital outreach team and one community healthcare team were established to facilitate early discharge. Each team consisted of a nurse, a physiotherapist and an occupational therapist. The hospital outreach team organised the transition from the hospital to the patient\'s home. The community healthcare team was responsible for rehabilitation and actual treatment for up to 5 weeks after discharge from the stroke unit. The nurse was the team leader and coordinator. The teams communicated and cooperated closely. Patients were discharged from the hospital to their own homes as early as possible.

Experimental group I, day unit rehabilitation: patients travelled from home to a local day rehabilitation unit to receive treatment from the community healthcare team. Treatment was mainly physiotherapy and occupational therapy and focused on impairment in body function as well as task-oriented training.

Experimental group II, home rehabilitation: patients received treatment from the community healthcare team in their own homes. Treatment was mainly physiotherapy and occupational therapy and focused on task-oriented training in daily activities.

The planned main difference between the experimental groups was the context in which patients received their rehabilitation interventions.

Control group, traditional treatment: patients followed a routine discharge procedure with outpatient therapy on an ad hoc basis. Treatment by various healthcare professionals depended on the patients' needs and consisted mostly of physiotherapy, either at home or in private physiotherapy practices. Other health professions could be involved (occupational therapy and home nursing); however, the interventions were uncoordinated and mainly unidisciplinary.

Patients in all groups received speech therapy on an outpatient basis if needed.

Outcomes and follow-up {#s2d}
----------------------

All patients were evaluated with a wide range of medical, ADL, physical capacity and self-report measures at baseline and 3 months after inclusion. Brain scans using CT or MRI were performed shortly after admission to the stroke unit.

### Primary outcome measure {#s2d1}

PASS was used to assess ability to maintain a position and to maintain equilibrium during positional changes such as turning in bed, sitting up from a supine position, standing up, picking an object off the floor and standing on one leg.[@R14] [@R18] Combined, these comprise a measure within the activity domain of the International Classification of Functioning, Disability and Health (ICF).[@R19] PASS contains 12 items (0--36, highest score best) and has shown high sensitivity to change in postural control during the first 3--6 months post stroke.[@R14] [@R20] [@R21] Smallest detectable change (SDC) is ≥4 points.[@R22] PASS has demonstrated high internal consistency, good psychometric properties and predictive ability for ADL function 1 year after stroke.[@R20]

### Secondary outcome measures {#s2d2}

The Trunk Impairment Scale-modified Norwegian version (TIS-modNV) was used to evaluate impairment of trunk control post stroke,[@R23] the ICF domain being body function.[@R24] [@R25] The scale consists of six ordinal items that assess postural control of the trunk in a sitting position. It has demonstrated good construct validity, excellent internal consistency and high inter-tester and test--retest reliability for the total score (0--16, highest score best). SDC is ≥3 points.[@R23]

Functional ambulation categories categorise the patient\'s walking ability in six levels (0--5, highest category best).[@R26] The ICF domain is activity. Stairs, and a 10 m indoor walking distance, is needed in order to discern between categories 4 and 5. The test has demonstrated good reliability, validity and sensitivity to change during the first 6 months post stroke.

Timed Up-and-Go (TUG)[@R27] [@R28] is a test of balance, walking speed and ADL. The patient rises from a chair, walks 3 m, turns, walks back to the chair and sits down. Time used for the entire sequence is measured. The ICF domain is activity.[@R16] TUG is sensitive to change over time, has shown predictive ability for walking outdoors unaided[@R28] and has demonstrated acceptable reliability and validity in stroke.[@R29] Time used was transformed to m/s before analysis.

The 5 m timed walk (5mTW)[@R30] [@R31] is a test for walking speed, the ICF domain being activity. 5mTW at a comfortable speed is seen to be the most responsive walking test during the first 5 weeks post stroke, and has been reported to correlate with functional ability and balance confidence.[@R31] A recommended 1--2 m acceleration and deceleration phase was used, and time transformed to m/s. This test was not included until the end of February 2009, and the first 13 patients were not tested.

Patients who were unable to walk were given a score of 0 m/s in the walking tests.

### Self-report measures {#s2d3}

Numerical Rating Scales[@R32] are 11-point scales (0--10, lowest score best), and were used to uncover the patient\'s own perception of stroke-related problems with walking, balance, ADL, safety in physical activity (ICF domain: activity), pain and tiredness (ICF domain: body function).

### Other background information measures {#s2d4}

NIHSS is used to assess initial impairment, including motor and sensory function, speech and language.[@R11] [@R12] The scale used in this study was a 13-item Norwegian version (0--34, lowest score best), where mild stroke=0--7, moderate=8--14 and severe ≥15.[@R13]

BI is a 10-item scale (0--100, highest score best) used to assess the patient\'s dependence on ADL function.[@R15] [@R16] Dependence on ADL is defined as \<95.[@R33] [@R34]

mRS is a 7-level scale (0--6, lowest score best) used to measure outcome related to dependency, defined as equivalent to mRS \>2.[@R17]

Sample size calculation {#s2e}
-----------------------

To detect a mean difference in change in PASS of 4 points (SDC) from baseline to 3 months between the three groups assuming an SD of 3.2 points[@R35] for the change scores at significance level 5% (α=0.05), at least 20 patients in each group would give a power of at least 90% (analysis of variance F-test; this assumes that the mean changes are equally spaced between the three groups; with a more extreme distribution, the power increases). The statistical program SamplePower V.2 was used to determine the power of the study. The ESD Stroke Bergen Study used a different main outcome measure than did this study, and the predetermined inclusion period of 3 years was therefore expected to yield a greater amount of data than was needed for our study alone.

Statistics {#s2f}
----------

Descriptive statistics were used for the background variables and baseline and change scores of the physical capacity tests and self-report measures. To compare baseline data of patients who were tested with PASS at baseline and at 3 months with those who were not tested with PASS at 3 months, either the independent t test or Mann-Whitney U test was used for continuous variables depending on the distribution, and the χ^2^ test was used for categorical variables.

One-way analysis of variance was used to compare baseline scores between the three groups. When data were not distributed normally or were categorical, the corresponding non-parametric statistical tests were used (Kruskal-Wallis, χ^2^, respectively).

The non-parametric statistical test (Kruskal-Wallis) was used to compare the difference in change between the groups as the change scores were not normally distributed. If a statistically significant difference (p\<0.05) between groups was found in the analysis, pairwise tests for independent groups were performed (Mann-Whitney U test) using significance level p=0.05/3=0.0167 to adjust for multiple comparisons. Simple (unadjusted), multiple (fully adjusted) and backward stepwise multiple linear regression analyses were performed for PASS scores at 3 months as the dependent variable on group allocation including age, gender, cohabitation, diagnosis, diabetes, previous stroke, previous nursing care, thrombolysis, baseline NIHSS scores and baseline scores of PASS. The statistical programs package SPSS V.21 (SPSS Inc, Chicago, Illinois, USA) was used for all data analyses.

Results {#s3}
=======

During the inclusion period, 1749 patients were admitted to the stroke unit, of which 1443 did not meet the inclusion criteria. The main reasons for exclusion were living outside of Bergen or not having suffered a confirmed stroke. This left 319 patients who were eligible to take part in the main trial, ESD Stroke Bergen. Of these, 13 declined to participate; 306 patients were willing to participate. These were randomised into three groups ([figure 1](#BMJOPEN2013004358F1){ref-type="fig"}). For this study, 21 patients who were not tested with PASS at baseline and 118 patients who were not discharged directly home after their stay in the stroke unit were excluded. This resulted in 167 eligible patients: 52 in the day unit group, 60 in the home rehabilitation group and 55 in the control group. In the day unit group, 25 (48%) were lost to follow-up, in the home-rehabilitation group 17 (28%) and in the control group 20 (36%), a total of 62 (37%). Three patients in total, one in the day unit group and two in the home rehabilitation group, did not receive the allocated intervention, but were tested at both points in time and were included in intention-to-treat analyses.

![Flow chart of patients allocated to the Balance and Walking study, from randomised groups of the Early Supported Discharge (ESD) Stroke Bergen study. PASS, Postural Assessment Scale for Stroke.](bmjopen2013004358f01){#BMJOPEN2013004358F1}

Baseline characteristics are shown in [table 1](#BMJOPEN2013004358TB1){ref-type="table"}. The patients who were not retested were older, fewer lived with a partner, and they had a higher incidence of previous stroke and previous nursing care.

###### 

Baseline characteristics of all patients (N=167) discharged home after stroke unit stay

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                               All\    Tested and retested with PASS\   Not retested with PASS\   p Value   Statistic                                                 
                                          N=167   n=105                            n=62                                                                                          
  --------------------------------------- ------- -------------------------------- ------------------------- --------- ----------- -------- ------ -------- -------- ----------- -----------
  Age; mean (SD), min, max                70.4    (13.2)                           29, 98                    69.1      (12.7)      29, 94   76.0   (12.2)   42, 98   *\<0.001*   t test

  Gender; n (%)                                                                                                                                                      0.333       χ^2^ test

   Male                                   95      \(57\)                                                     63        \(60\)               32     \(52\)                        

   Female                                 72      \(43\)                                                     42        \(40\)               30     \(48\)                        

  Living with partner; n (%)              103     \(62\)                                                     77        \(73\)               26     \(42\)            *\<0.001*   χ^2^ test

  Stroke diagnosis; n (%)                                                                                                                                            0.090       χ^2^ test

   Ischaemic                              152     \(91\)                                                     99        \(94\)               53     \(86\)                        

   Haemorrhagic                           15      \(9\)                                                      6         \(6\)                9      \(15\)                        

  Localisation of lesion; n (%)                                                                                                                                      0.457       χ^2^ test

   Right hemisphere                       60      \(36\)                                                     36        \(34\)               24     \(38\)                        

   Left hemisphere                        71      \(43\)                                                     46        \(44\)               25     \(40\)                        

   Bilateral                              7       \(4\)                                                      5         \(5\)                2      \(3\)                         

   Brainstem                              19      \(11\)                                                     14        \(13\)               5      \(8\)                         

   Cerebellum                             10      \(6\)                                                      4         \(4\)                6      \(10\)                        

  Most affected body half; n (%)                                                                                                                                     0.942       χ^2^ test

   Right                                  94      \(56\)                                                     60        \(57\)               34     \(55\)                        

   Left                                   70      \(42\)                                                     43        \(41\)               27     \(43\)                        

   Bilateral                              3       \(7\)                                                      2         \(2\)                1      \(2\)                         

  Thrombolysis; n (%)                     20      \(12\)                                                     13        \(12\)               7      \(11\)            1.000       χ^2^ test

  Diabetes; n (%)\*                       27      \(16\)                                                     19        \(18\)               8      \(13\)            0.514       χ^2^ test

  Previous stroke; n (%)†                 38      \(23\)                                                     18        \(17\)               20     \(32\)            *0.036*     χ^2^ test

  Previous nursing care; n (%)            12      \(7\)                                                      4         \(4\)                8      \(8\)             *0.034*     χ^2^ test

  Days stroke unit; mean (SD), min, max   8.6     \(5\)                            2, 43                     8.7       \(4\)       3, 22    8.4    \(6\)    2, 43    0.732       t test
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Significant values (p\<0.05) marked in italic; the p values refer to the comparison between the two groups.

\*Missing information on one patient.

†Missing information on two patients.

The patients who were retested after 3 months demonstrated higher (better) baseline scores on PASS, BI, TUG and 5mTW than did the patients who were not retested ([table 2](#BMJOPEN2013004358TB2){ref-type="table"}). Both patient groups had rather high PASS scores at baseline, ranging between 17 and 36 (median 32 and 30 of retested and not-retested patients, respectively), that is, they had mostly mild-to-moderate disability.

###### 

Comparison of physical function at baseline between patients tested with PASS at both time points and patients who were not retested with PASS at 3 months, N=167

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables     Tested and retested with PASS\                       Not retested with PASS\   p Value        Statistic                                                             
                n=105                                                n=62                                                                                                           
  ------------- -------------------------------- -------- ---------- ------------------------- -------------- ----------- -------- ---------- ---------- -------------- ----------- -----------
  PASS          105                                       32         \(5\)                     17, 36         62                   30         \(5\)      18, 36         *\<0.001*   M-W

  FAC; n (%)    105                                       5          \(1\)                     1, 5           62                   4          \(2\)      0, 5           0.293       χ^2^ test

                                                                                                                                                                                    

   0            0                                (−)                                                          1           \(2\)                                                     

   1            2                                \(2\)                                                        2           \(3\)                                                     

   2            5                                \(5\)                                                        4           \(7\)                                                     

   3            17                               \(16\)                                                       17          \(27\)                                                    

   4            26                               \(25\)                                                       13          \(21\)                                                    

   5            55                               \(52\)                                                       25          \(40\)                                                    

  NIHSS         105                                       3          \(2\)                     0, 13          62                   3          \(3\)      0, 26          0.378       M-W

  BI\*          104                                       100        \(0\)                     65, 100        62                   100        \(10\)     5, 100         *0.043*     M-W

  mRS           105                                       2          \(1\)                     0, 4           62                   2          \(1\)      0, 4           0.233       χ^2^ test

   mRS; n (%)                                                                                                                                                                       

   0            8                                \(8\)                                                        3           \(5\)                                                     

   1            23                               \(22\)                                                       12          \(19\)                                                    

   2            59                               \(56\)                                                       29          \(47\)                                                    

   3            11                               \(11\)                                                       14          \(23\)                                                    

   4            4                                \(4\)                                                        4           \(7\)                                                     

                                                                                                                                                                                    

                **n**                                     **Mean**   **(SD)**                  **Min, max**   **n**                **Mean**   **(SD)**   **Min, max**               

                                                                                                                                                                                    

  TIS-modNV     105                                       10.73      (3.64)                    3, 16          62                   9.43       (3.90)     1, 16          0.799       t test

  TUG m/s       105                                       0.59       (0.27)                    0.00, 1.27     62                   0.41       (0.26)     0.00, 1.00     *\<0.001*   t test

  5mTW m/s†     94                                        0.99       (0.37)                    0.00, 1.84     59                   0.78       (0.40)     0.00, 1.62     *0.002*     t test
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Significant values marked in italic.

\*Missing information on one patient.

†13 Patients were not tested at baseline.

5mTW, 5 m timed walk; BI, Barthel Index; FAC, functional ambulation categories; M-W, Mann-Whitney U test; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PASS, Postural Assessment Scale for Stroke; TIS-modNV, Trunk Impairment Scale modified Norwegian version; TUG, timed Up-and-Go.

Comparisons between the groups at baseline demonstrated no difference for any physical outcome measure ([table 3](#BMJOPEN2013004358TB3){ref-type="table"}). The median score for PASS was high, and the mean (SD) walking speed (5mTW) was above community walking speed, estimated as ≥0.8 m/s[@R36] [@R37] for all groups. The mean (SD) length of stay in the stroke unit was 8.6 (4.8) days with no significant difference between the groups, p=0.948; day unit, mean (SD), minimum--maximum: 8.6 (3.3), 3--17; home rehabilitation: 8.7 (3.9), 3--18; control: 8.4 (4.5), 3--22.

###### 

Baseline scores of the physical and self-report measures, and comparison between experimental and control groups (N=167)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables            Day unit\   Home rehabilitation\   Control\       p Value   Statistic                                                                                                
                       n=52        n=60                   n=55                                                                                                                              
  -------------------- ----------- ---------------------- -------------- --------- ----------- ---------- -------------- ----- ---------- ---------- -------------- ------- ----------- --- --
  PASS                 31          \(6\)                  18, 36                   31          \(5\)      17, 36               31         \(3\)      20, 36         0.964   K-W             

  FAC                  5           \(2\)                  0, 5                     4           \(2\)      1, 5                 5          \(2\)      1, 5           0.365   χ^2^ test       

  FAC; n (%)                                                                                                                                                                                

   0                   1           \(19\)                                                      0 (−)                                      0 (−)                                             

   1                   0           (−)                                                         2 (3)                                      2 (4)                                             

   2                   4           \(8\)                                                       4 (7)                                      1 (2)                                             

   3                   12          \(23\)                                                      11 (18)                                    11 (20)                                           

   4                   8           \(15\)                                                      19 (32)                                    12 (22)                                           

   5                   27          \(52\)                                                      24 (40)                                    29 (53)                                           

  NIHSS                3           \(3\)                  1, 25                    3           \(3\)      0, 11                2          \(3\)      0, 26          0.275   K-W             

  BI\*                 100         \(0\)                  5, 100                   100         \(9\)      50, 100              100        \(5\)      50, 100        0.390   K-W             

  mRS                                                                                                                                                               0.971   χ^2^ test       

  mRS; n (%)                                                                                                                                                                                

   0                   4           \(8\)                                                       4 (7)                                      3 (6)                                             

   1                   13          \(25\)                                                      11 (18)                                    11 (20)                                           

   2                   27          \(52\)                                                      32 (53)                                    29 (53)                                           

   3                   7           \(14\)                                                      9 (15)                                     9 (17)                                            

   4                   1           \(2\)                                                       4 (7)                                      3 (6)                                             

                                                                                                                                                                                            

                       **Mean**    **(SD)**               **Min, max**             **Mean**    **(SD)**   **Min, max**   * *   **Mean**   **(SD)**   **Min, max**                           

                                                                                                                                                                                            

  TIS-modNV            10.48       (3.95)                 1, 16                    9.52        (3.51)     1, 16                10.73      (3.86)     1, 16          0.192   ANOVA           

  TUG m/s              0.52        (0.30)                 0.00, 1.15               0.52        (0.27)     0.00, 1.27           0.53       (0.28)     0.00, 1.13     0.988   ANOVA           

  5mtW m/s             0.88        (0.41)                 0.00, 1.46               0.91        (0.39)     0,00, 1.56           0.93       (0.41)     0.00, 1.84     0.830   ANOVA           

  NRS†                                                                                                                                                                                      

   Walking             3.5         (2.7)                  0, 10                    3.6         (2.8)      0, 10                3.0        (2.7)      0, 10          0.444   ANOVA           

   Balance             3.4         (2.8)                  0, 10                    4.1         (2.9)      0, 10                3.3        (2.6)      0, 10          0.245   ANOVA           

   ADL                 2.6         (2.7)                  0, 10                    3.3         (2.9)      0, 10                2.2        (2.5)      0, 8           0.084   ANOVA           

   Physical activity   2.7         (3.0)                  0, 10                    3.0         (2.9)      0, 10                2.3        (2.2)      0, 8           0.420   ANOVA           

   Pain                1.1         (1.9)                  0, 9                     1.3         (2.4)      0, 10                1.3        (2.1)      0, 7           0.865   ANOVA           

   Tiredness           3.1         (2.7)                  0, 10                    3.5         (2.5)      0, 10                3.4        (2.8)      0, 8           0.810   ANOVA           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Missing BI: one control.

†Missing NRS 1, NRS 2, NRS 3, NRS 4, NRS 6: two in day unit group, two in home rehabilitation group, two in control group; missing NRS 5: one in day unit group, two in home rehabilitation group, two in control group.

5mTW, 5 m timed walk; ANOVA, analysis of variance; BI, Barthel Index; FAC, functional ambulation categories; K-W, Kruskal-Wallis test; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NRS, Numerical Rating Scale; PASS, Postural Assessment Scale for Stroke; TIS-modNV, Trunk Impairment Scale modified Norwegian version; TUG, timed Up-and-Go.

Because of the substantial number of patients excluded or lost to follow-up after randomisation to the RCT study, we compared baseline characteristics and test scores of patients who were included in the study. There were no differences between the day unit, home rehabilitation and control groups for any background characteristics (web-only file).

The mean (SD) time between test and retest was 13.4 (1.7) weeks, with no difference between the groups. There was no statistically significant difference in loss to follow-up between the groups, p=0.097, and no difference in change between the groups for the main outcome PASS ([table 4](#BMJOPEN2013004358TB4){ref-type="table"}). A significant difference in change between the groups was shown for TIS-modNV and for self-reports on walking and ADL. Patients in the home rehabilitation group showed greater trunk control improvement than did those in the day unit and control groups. However, pairwise analyses adjusted for multiple comparisons were non-significant: day unit versus home rehabilitation, p=0.031; day unit versus control, p=0.886; home rehabilitation versus control, p=0.040. Self-report on problems with walking demonstrated greatest improvement in the day unit group, with pairwise analyses showing a significantly greater improvement for those in the day unit group as compared with the control group: day unit versus home rehabilitation, p=0.215; day unit versus control, p=0.004; home rehabilitation versus control, p=0.126. Self-report on ADL demonstrated that patients in the day unit and home rehabilitation groups improved more than did those in the control group, with a significant difference between the home rehabilitation and control groups: day unit versus home rehabilitation, p=0.774; day unit versus control, p=0.036; home rehabilitation versus control, p=0.006. No other pairwise comparisons demonstrated significant differences in change. The patients in the day unit group showed improvement above a clinically important change in walking (0.175 m/s).

###### 

Between group comparisons of change (3 month--baseline) scores in the physical and self-report measures (N=105)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables   Day unit\           Home rehabilitation\   Control\        p Value\*                                                                                          
              n=27                n=43                   n=35                                                                                                               
  ----------- ------------------- ---------------------- --------------- ---------------- -------- -------------- ---------------- -------- --------------- --------------- ---------
  PASS        0                   \(4\)                  −0.25 to 1.51   1                \(2\)    0.29 to 2.13   1                \(3\)    0.24 to 2.10    0.832           

  TIS-modNV   2                   \(3\)                  0.28 to 2.31    4                \(3\)    1.80 to 3.78   1                \(3\)    0.56 to 2.53    *0.044*         

  FAC         0                   \(1\)                  0.33 to 1.08    1                \(1\)    0.48 to 1.14   0                \(1\)    0.20 to 0.71    0.330           

  NRS†                                                                                                                                                                      

   1          Walking             −2                     \(3\)           −2.92 to −0.93   −1       \(3\)          −2.12 to −0.41   0        \(1\)           −1.24 to 0.41   *0.021*

   2          Balance             --1                    \(3\)           −2.18 to −0.34   −1       \(3\)          −2.29 to −0.56   0        \(2\)           −1.25 to 0.08   0.381

   3          ADL                 --2                    \(4\)           −3.37 to −1.08   −2       \(5\)          −3.18 to −1.54   0        \(2\)           −1.51 to 0.34   *0.016*

   4          Physical activity   −1                     \(3\)           −2.43 to −0.61   −1       \(4\)          −2.46 to −0.93   0        \(1\)           −1.13 to 0.13   0.063

   5          Pain                0                      \(2\)           −1.22 to 0.18    0        \(0\)          −1.12 to 0.17    0        \(2\)           −0.96 to 0.60   0.489

   6          Tiredness           0                      \(2\)           −1.68 to 0.49    0        \(3\)          −0.90 to 0.57    0        \(4\)           −0.98 to 0.87   0.739

                                  *Mean*                 *(SD)*          *95% CI*         *Mean*   *(SD)*         *95% CI*         *Mean*   *(SD)*          *95% CI*        

  TUG         0.10                (0.14)                 0.04 to 0.15    0.11             (0.21)   0.05 to 0.18   0.05             (0.15)   −0.05 to 0.10   0.303           

  5mTW        0.26                (0.26)                 0.14 to 0.37    0.16             (0.35)   0.05 to 0.28   0.12             (0.22)   0.04 to 0.20    0.123           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Significant values marked in italic.

\*Non-parametric analysis: Kruskal-Wallis test.

†Negative values indicate improvement in condition.

5mTW, 5 m timed walk; ADL, activities of daily living; BI, Barthel Index; FAC, functional ambulation categories; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NRS, Numerical Rating Scale; PASS, Postural Assessment Scale for Stroke; TIS-modNV, Trunk Impairment Scale-modified Norwegian version; TUG, timed Up-and-Go.

Multiple regression analyses for PASS at 3 months demonstrated a significant negative effect of increased age (b=−0.070), positive effect of higher baseline PASS scores (b=0.394), positive effect of not having previous cerebral lesion (b=2.621) and positive effect of not having had previous nursing care (b=1.220) with an explained variance of 63% in the final model after backward stepwise selection. The control group had higher means than did the other groups, that is, the unadjusted differences in means (95% CI) between the control and day unit groups were −0.194 (−1.823 to 1.436), and between the control and home rehabilitation groups −0.599 (−2.048 to 0.840). Group allocation was not a significant predictor for PASS, either unadjusted (p=0.720) or adjusted for the other variables.

The total intensity of treatment from the community healthcare team amounted to mean (SD), minimum--maximum: 22.0 (9.5), 4.0--50.1 h for the day unit group and 16.6 (9.0), 0.5--48.5 h for the home rehabilitation group. The mean difference (95%CI) between the groups was 5.4 h (1.61, 9.12), p=0.006. The duration lasted 4.4 weeks for the day unit patients and 4.2 weeks for the home rehabilitation patients, p=0.240. The intervention was mainly given by a physiotherapist or occupational therapist. In addition, patients were advised to do exercises at home 2 days/week, mainly related to activities and participation, individually adjusted to the patients' needs in time and content.[@R38]

Discussion {#s4}
==========

We did not find any significant differences in change between the day unit, home rehabilitation or control groups for the primary outcome measure PASS, or for the length of stroke unit stay. The patients in this study were shown to have mainly mild-to-moderate disability after stroke. Significant differences in change between the three groups were shown for the secondary outcome measures of trunk control and self-report on walking and ADL. Pairwise comparisons demonstrated a larger improvement in self-reported walking in the day unit group as compared with the control group, and a greater improvement in self-reported ADL after home rehabilitation as compared with the control group. As expected, age and baseline scores of PASS explained most of the change in PASS at 3 months.

This study\'s strengths lie in the use of objective and self-report outcome measures by blinded assessors for the comparison of balance and walking between study groups, and in the body function and activity domains of the ICF being captured by the tests. This study was designed with early supported discharge for the day unit and home rehabilitation groups in mind; unexpectedly, however, patients in the control group were discharged from the stroke unit just as early. The acute management of stroke in stroke units has changed over the last decade and is constantly developing, especially for patients with ischaemic strokes.[@R13] In addition, health authorities in the primary healthcare system in Norway are required to offer appropriate care and rehabilitation for patients discharged after hospital treatment. As a consequence, patients tend to be discharged earlier than was previously the case. Patients with mild-to-moderate disability seem to be most suitable for early supported discharge.[@R3] [@R4] [@R39] The patients who were discharged directly home were shown to have an overall mild-to-moderate level of function at baseline, scoring a median of 32 points on PASS. A BI above 80/100 is defined as mild disability.[@R40] Only a few patients were in the severe category as shown in [table 3](#BMJOPEN2013004358TB3){ref-type="table"}. Our results are therefore representative for rehabilitation models that aim for early supported discharge. However, the results of this study cannot be extended to patients with stroke with poorer baseline physical function.

We did not find any differences in change between the groups in regard to PASS. Spontaneous recovery,[@R41] [@R42] combined with generally high baseline scores that imply a ceiling effect, might explain this result. However, no differences were found in previous studies between experimental and control groups on early supported discharge where physical capacity tests were used as the main outcome.[@R6] The outcome measures used in those studies differed from those used in this study. For example, walking was tested differently in Widen-Holmquist *et al*,[@R8] Askim *et al*[@R6] and in our study, and therefore no direct comparison between the studies is possible.

We found a difference between the groups for trunk control which improved above SDC in the home rehabilitation patients. A relationship between trunk control and functional ability in daily life in patients after stroke has also been indicated in other studies.[@R35] [@R43] Self-reported ADL improved more in the day unit and home rehabilitation groups, with pairwise comparisons demonstrating a significantly greater change only for the home rehabilitation group as compared with the control group. Differences between groups in ADL function have not been reported in previous studies on ESD as compared with ordinary service,[@R1] [@R3] but patients' perception of problems with ADL has not been reported previously. We would have expected that patients who receive treatment to improve daily tasks in the functional context of their own homes would improve these skills more than patients in the day unit and control groups. It is recommended that such treatment be meaningful and repetitive,[@R47] [@R48] and repetitive task-oriented training has been found to result in small amounts of improvement in ADL,[@R49] which may explain why the home rehabilitation group experienced most improvement. The groups demonstrated a mean moderate trunk control at baseline, and for patients with this level of trunk control, home rehabilitation would therefore seem to be most effective.

The patients' perception of problems with walking improved most in the day unit group, with a significant difference demonstrated between the day unit and control groups. Also, walking speed improved above clinically important change, estimated as ≥0.175 m/s[@R30] in the day unit group, but not in the home rehabilitation and control groups ([table 4](#BMJOPEN2013004358TB4){ref-type="table"}). Interestingly, a recent study found a significant relationship between self-reported walking ability and gait performance in chronic patients with stroke,[@R50] which supports our finding. Travelling to a day unit several times per week might have given the patients enhanced gait training effects[@R9] as well as experience with a larger area in which to move and varied environments. In addition, the day unit patients received on average more treatment from the community healthcare team than the home rehabilitation group. More therapy time and more intensity of therapy seem to be beneficial for functional outcome[@R51] [@R52] and could explain why walking seemed to improve more in this group. For walking speed, day unit rehabilitation would therefore seem most effective.

Whether a mean of 22.0 and 16.6 h of treatment over a 4-week period is considered intensive in a subacute phase after stroke remains to be explored. Our patients had mostly mild-to-moderate disability and received an intensity and duration of treatment adjusted to their individual needs. There was a similar maximum intensity given to those patients with the greatest need in the day unit and home rehabilitation groups.

The patients in the original trial (ESD Stroke Bergen) were randomised to three groups, making them comparable in regard to background variables and test scores. As a large portion of the patients were excluded or lost to follow-up, we could not be sure that the patients who remained in the groups in this study were still comparable. However, analysis of our study patients demonstrated no statistically significant difference between the groups, either in demographic or in test variables at baseline. However, there was a non-significant difference in loss to follow-up between the groups. The loss to follow-up is a weakness in the study. Patients who were lost to follow-up were older, more of them lived alone and they had a poorer baseline function; therefore, attending retesting might have been too challenging. Real differences might therefore have gone undetected. A recommendation for future studies would be to undertake retesting in the patients' homes if possible, to minimise loss to follow-up. Another weakness in this study is the fact that we did not register the extent to which the patients in the control group had received treatment. When comparing outcomes of the groups, this knowledge would have been advantageous.

More research is needed to investigate which rehabilitation context is most effective for various aspects of physical function, as well as in patients with poorer baseline function.

Conclusion {#s5}
==========

There was no difference in change of postural balance assessed by PASS at 3 months after stroke. For the secondary outcomes, home rehabilitation and day unit treatment tended to be more effective for trunk control, perception of walking and ADL than traditional treatment. Day unit patients improved above clinically important change in walking speed.
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